Abstract:Aims/hypothesisWe examined whether measures of glycaemic variability (GV), assessed by continuous glucose monitoring (CGM) and self-monitoring of blood glucose (SMBG), can complement or replace measures of beta cell function and insulin action in detecting the progression of preclinical disease to type 1 diabetes.MethodsTwenty-two autoantibody-positive (autoAb+) first-degree relatives (FDRs) of patients with type 1 diabetes who were themselves at high 5-year risk (50%) for type 1 diabetes underwent CGM, a hyperglycaemic clamp test and OGTT, and were followed for up to 31 months. Clamp variables were used to estimate beta cell function (first-phase [AUC5–10 min] and second-phase [AUC120–150 min] C-peptide release) combined with insulin resistance (glucose disposal rate; M120–150 min). Age-matched healthy volunteers (n = 20) and individuals with recent-onset type 1 diabetes (n = 9) served as control groups.ResultsIn autoAb+ FDRs, M120–150 min below the 10th percentile (P10) of controls achieved 86% diagnostic efficiency in discriminating between normoglycaemic FDRs and individuals with (impending) dysglycaemia. M120–150 min outperformed AUC5–10 min and AUC120–150 min C-peptide below P10 of controls, which were only 59–68% effective. Among GV variables, CGM above the reference range was better at detecting (impending) dysglycaemia than elevated SMBG (77–82% vs 73% efficiency). Combined CGM measures were equally efficient as M120–150 min (86%). Daytime GV variables were inversely correlated with clamp variables, and more strongly with M120–150 min than with AUC5–10 min or AUC120–150 min C-peptide.Conclusions/interpretationCGM-derived GV and the glucose disposal rate, reflecting both insulin secretion and action, outperformed SMBG and first- or second-phase AUC C-peptide in identifying FDRs with (impending) dysglycaemia or diabetes. Our results indicate the feasibility of developing minimally invasive CGM-based criteria for close metabolic monitoring and as outcome measures in trials.

The Relation of Diabetes Complications to a New Interpretation of Glycaemic Variability from Continuous Glucose Monitoring in People with Type 1 Diabetes

Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring

Potential Benefits of Continuous Glucose Monitoring for Predicting Vascular Outcomes in Type 2 Diabetes: A Rapid Review of Primary Research

Glycemic variability: Measurement, target, impact on complications of diabetes and does it really matter?

Unveiling the Spectrum of Glucose Variability: A Novel Perspective on FreeStyle Libre Monitoring Data

The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control

Diabetic peripheral neuropathy and glycemic variability assessed by continuous glucose monitoring: A systematic review and meta-analysis

HbA1c Variability As an Independent Risk Factor for Microvascular Complications in Type 1 Diabetes

Research progress on the association between glycemic variability index derived from CGM and cardiovascular disease complications

Glycemic variability assessed using continuous glucose monitoring in individuals without diabetes and associations with cardiometabolic risk markers: A systematic review and meta-analysis

Current concepts and clinical importance of glycemic variability

Glycemic Variability Assessed by Continuous Glucose Monitoring and the Risk of Diabetic Retinopathy in Latent Autoimmune Diabetes of the Adult and Type 2 Diabetes

Clinical implications and pharmacological considerations of glycemic variability in patients with type 2 diabetes mellitus

Relationship of Glucose Variability With Glycated Hemoglobin and Daily Mean Glucose: A Post Hoc Analysis of Data From 5 Phase 3 Studies

Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes

Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study

Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial

Glycemic Variability Evaluated by Continuous Glucose Monitoring System is Associated with the 10-Y Cardiovascular Risk of Diabetic Patients with Well-Controlled HbA1c.

Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers!

To What Extent Is HbA1c Associated with Glycemic Variability in Patients with Type 1 Diabetes? A Retrospective, Noninterventional Study

Implications of glycemic risk index across different levels of glycated hemoglobin (HbA1c) in type 1 diabetes